Skip to main content
Targeted SNCA Downregulation for Parkinson’s and Synucleinopathies

Targeted SNCA Downregulation for Parkinson’s and Synucleinopathies

Unmet Need Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people globally and 1 million in the U.S. The disease is characterized by involuntary movements such as tremors, stiffness,…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us